The group's principal activity is to sponsor and conduct research and development on biopharmaceutical products. It is in the clinical-stage of developing antiangiogenesis therapeutic products. These products inhibit abnormal blood vessel growth associated with a broad range of diseases such as cancer, blindness atherosclerosis and endometriosis. The group's core technologies also include a blood cell permeation device, which is designed to enhance the ability of red blood cells to deliver oxygen to organs and tissues. This device may also be used to deliver drugs, genes or other therapeutic agents that otherwise would not readily diffuse through blood cell membranes. The antiangiogenic product candidates include endostatin, panzem and angiostatin. These products are used to inhibit the growth of tumor-feeding blood vessels.
